ICU Medical Inc
NASDAQ:ICUI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (55.7), the stock would be worth $187.92 (45% upside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 38.5 | $129.96 |
0%
|
| 3-Year Average | 55.7 | $187.92 |
+45%
|
| 5-Year Average | 51.1 | $172.57 |
+33%
|
| Industry Average | 19.2 | $64.98 |
-50%
|
| Country Average | 19.6 | $66.24 |
-49%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
$4B
|
/ |
Jan 2026
$109.3m
|
= |
|
|
$4B
|
/ |
Dec 2026
$356.1m
|
= |
|
|
$4B
|
/ |
Dec 2027
$392.4m
|
= |
|
|
$4B
|
/ |
Dec 2028
$441.5m
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
ICU Medical Inc
NASDAQ:ICUI
|
3.2B USD | 38.5 | 4 383.1 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.8T JPY | 34.1 | 39.1 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
62.6B USD | 0 | 0 | |
| CH |
|
Alcon AG
SIX:ALC
|
30.7B CHF | 29.3 | 39.2 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
97.7B DKK | 15.8 | 25.3 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
13.6B USD | 19.8 | 33.1 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.7B GBP | 19.2 | 35.6 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
6B USD | 56.3 | -16.5 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
927.6B JPY | 33.8 | 52.4 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8.3T KRW | -79.9 | -37.7 | |
| US |
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
5.4B USD | 18.2 | 23.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.6 |
| Median | 19.6 |
| 70th Percentile | 27.8 |
| Max | 1 826 183.2 |
Other Multiples
ICU Medical Inc
Glance View
ICU Medical Inc. emerged as an intriguing player in the healthcare sector, focusing on a mission-critical niche within the industry—safety and efficiency in medical devices for infusion therapy, oncology, and critical care applications. Founded with an innovative spirit, the company carved out a reputation by addressing a key challenge in the medical field: preventing bloodstream infections and the exposure of healthcare professionals to hazardous substances. This focus led to the development of specialized devices such as needle-free connectors and closed system transfer devices, which are integral to minimizing contamination risks. These innovations not only improved patient outcomes but also enhanced the working conditions of medical professionals, underpinning ICU Medical’s growth trajectory. ICU Medical generates revenue by designing and manufacturing these life-saving devices, which are distributed across hospitals and healthcare facilities worldwide. The company's business model revolves around creating products that align with strict regulatory standards, ensuring both safety and superiority in healthcare settings. As they ventured into diverse product lines, such as infusion pumps and systems, the firm leveraged strategic acquisitions to expand market reach and technological capabilities. These initiatives underscored ICU Medical's commitment to operational synergy and product innovation, enabling the company to remain competitive and continue scaling its operations in a constantly evolving healthcare landscape. With a steady focus on both organic growth and strategic partnerships, ICU Medical remains a crucial player in the global health economy, dedicated to advancing patient care and the efficiency of healthcare delivery systems.